Interference of antibacterial agents with phagocyte functions: Immunomodulation or "immuno-fairy tales"?

被引:167
作者
Labro, MT [1 ]
机构
[1] CHU X Bichat Cl Bernard, Fac Xavier Bichat, INSERM, U479, F-75018 Paris, France
关键词
D O I
10.1128/CMR.13.4.615-650.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Professional phagocytes (polymorphonuclear neutrophils and monocytes/macrophages) are a main component of the immune system. These cells are involved in both host defenses and various pathological settings characterized by excessive inflammation. Accordingly, they are key targets for immunomodulatory drugs, among which antibacterial agents are promising candidates. The basic and historical concepts of immunomodulation will first be briefly reviewed. Phagocyte complexity will then be unravelled (at least in terms of what we know about the origin, subsets, ambivalent roles, functional capacities, and transductional pathways of this cell and how to explore them). The core subject of this review will be the manu possible interactions between antibacterial agents and phagocytes, classified according to demonstrated or potential clinical relevance (e.g., neutropenia, intracellular accumulation, and modulation of bacterial virulence). A detailed review of direct in vitro effects will be provided for the various antibacterial drug families, followed by a discussion of the clinical relevance of these effects in two particular settings: immune deficiency and inflammatory diseases. The prophylactic and therapeutic rise of immunomodulatory antibiotics will be considered before conclusions me drawn about the emerging (optimistic) vision of future therapeutic prospects to deal with largely unknown new diseases and new pathogens by using new agents, new techniques, and a better understanding of the phagocyte in particular and the immune system in general.
引用
收藏
页码:615 / +
页数:37
相关论文
共 417 条
  • [21] NADPH oxidase: An update
    Babior, BM
    [J]. BLOOD, 1999, 93 (05) : 1464 - 1476
  • [22] BABIOR BM, 1984, BLOOD, V64, P959
  • [23] BAKER H J, 1954, Ann N Y Acad Sci, V58, P1232, DOI 10.1111/j.1749-6632.1954.tb45905.x
  • [24] DELIVERY OF ANTIMICROBIALS TO INFECTED TISSUE MACROPHAGES
    BAKKERWOUDENBERG, IAJM
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1995, 17 (01) : 5 - 20
  • [25] Banerjee G, 1998, ANTIMICROB AGENTS CH, V42, P348
  • [26] CEFODIZIME - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE
    BARRADELL, LB
    BROGDEN, RN
    [J]. DRUGS, 1992, 44 (05) : 800 - 834
  • [27] BARRETT JF, 1995, EXPERT OPIN INV DRUG, V4, P551
  • [28] BARSKI G, 1948, ANN I PASTEUR PARIS, V74, P1
  • [29] PRIMITIVE CYTOKINES - HARBINGERS OF VERTEBRATE DEFENSE
    BECK, G
    HABICHT, GS
    [J]. IMMUNOLOGY TODAY, 1991, 12 (06): : 180 - 183
  • [30] Reduction by cefodizime of the pulmonary inflammatory response induced by heat-killed Streptococcus pneumoniae in mice
    Bergeron, Y
    Ouellet, N
    Deslauriers, AM
    Simard, M
    Olivier, M
    Bergeron, MG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) : 2527 - 2533